---
title: "Anti-inflammatory effects of GLP-1 receptor agonists: review of evidence and clinical implications"
id: "pubmed-42219869"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42219869"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42219869/"
doi: "10.1210/clinem/dgag218"
published_at: "2026-08-13T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Anti-inflammatory effects of GLP-1 receptor agonists: review of evidence and clinical implications
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42219869
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42219869/)
- **DOI:** [10.1210/clinem/dgag218](https://doi.org/10.1210%2Fclinem%2Fdgag218)
- **Published At:** 2026-08-13T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- **GLP-1 receptor agonists (GLP-1RA)** are established therapies for type 2 diabetes and obesity, lowering glucose, reducing body weight, and improving **cardiovascular outcomes**. - Beyond metabolic benefits, accumulating evidence from preclinical models and clinical trials suggests **anti-inflammatory** effects of GLP-1RA across multiple organ systems. - Chronic inflammation underlies many common diseases—diabetes, cardiovascular disease, neurodegeneration, and inflammatory bowel disease—creating a rationale to evaluate GLP-1RA as immunomodulatory agents. - The review synthesizes data from animal and human studies showing immunomodulatory signals but does not provide pooled quantitative effect sizes in the abstract; details of individual studies were presented in the full text. - Potential translational opportunities include dual **cardiometabolic** and anti-inflammatory protection, raising interest in broader therapeutic applications beyond glucose and weight control. - Key unresolved issues highlighted are causality, the precise molecular mechanisms by which GLP-1RA exert anti-inflammatory effects, and how well these effects translate to effective treatments for nonmetabolic inflammatory diseases. - The article identifies diverse clinical areas of interest including autoimmune disease, neurodegeneration, inflammatory bowel disease, infectious diseases, sepsis, and cardiovascular disease, reflecting broad research pathways. - The review is published in J Clin Endocrinol Metab (2026), authored by Luis Quintana et al., and indexed with PMID 42219869 and DOI 10.1210/clinem/dgag218.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42219869/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42219869%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42219869/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42219869/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42219869/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42219869/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42219869/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42219869%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42219869%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42219869/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42219869/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42219869/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42219869/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--academic.oup.com-images-jcem_pubmed.png) Silverchair Information Systems ](https://academic.oup.com/jcem/article-lookup/doi/10.1210/clinem/dgag218 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42219869/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42219869/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42219869/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42219869/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42219869/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42219869/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42219869/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42219869/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42219869/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42219869/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42219869/#linkout) Title & authors Abstract Similar articles Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources Review J Clin Endocrinol Metab Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Endocrinol+Metab%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Endocrinol+Metab%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) . 2026 Aug 13;111(9):e2076-e2085. doi: 10.1210/clinem/dgag218. # Anti-inflammatory effects of GLP1-RA drugs [Luis Quintana](https://pubmed.ncbi.nlm.nih.gov/?term=Quintana+L&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#full-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany."), [Nadim Tabaza](https://pubmed.ncbi.nlm.nih.gov/?term=Tabaza+N&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#full-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany."), [Berkan Kurt](https://pubmed.ncbi.nlm.nih.gov/?term=Kurt+B&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#full-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany."), [Florian Kahles](https://pubmed.ncbi.nlm.nih.gov/?term=Kahles+F&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#full-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany.") Affiliations Expand ### Affiliation * 1 Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany. * PMID: **42219869** * DOI: [ 10.1210/clinem/dgag218 ](https://doi.org/10.1210/clinem/dgag218) Item in Clipboard Review # Anti-inflammatory effects of GLP1-RA drugs Luis Quintana et al. J Clin Endocrinol Metab. 2026. Show details Display options Display options Format Abstract PubMed PMID J Clin Endocrinol Metab Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Endocrinol+Metab%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Endocrinol+Metab%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) . 2026 Aug 13;111(9):e2076-e2085. doi: 10.1210/clinem/dgag218. ### Authors [Luis Quintana](https://pubmed.ncbi.nlm.nih.gov/?term=Quintana+L&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#short-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany."), [Nadim Tabaza](https://pubmed.ncbi.nlm.nih.gov/?term=Tabaza+N&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#short-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany."), [Berkan Kurt](https://pubmed.ncbi.nlm.nih.gov/?term=Kurt+B&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#short-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany."), [Florian Kahles](https://pubmed.ncbi.nlm.nih.gov/?term=Kahles+F&cauthor_id=42219869)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42219869/#short-view-affiliation-1 "Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany.") ### Affiliation * 1 Department of Internal Medicine I-Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen D-52074, Germany. * PMID: **42219869** * DOI: [ 10.1210/clinem/dgag218 ](https://doi.org/10.1210/clinem/dgag218) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RA) are established treatment options for type 2 diabetes and obesity. This class of medications has redefined care by lowering glucose, reducing body weight, and improving cardiovascular outcomes. Beyond metabolic benefits, accumulating evidence indicates that GLP-1RA exert direct anti-inflammatory effects across multiple organ systems. Chronic inflammation is a driving force behind many prevalent diseases, including diabetes, cardiovascular disease, neurodegenerative disorders, and inflammatory bowel disease. This review summarizes the current evidence of the anti-inflammatory effects of GLP-1RA, highlighting data from preclinical models and clinical trials across different diseases. By targeting both metabolic and inflammatory pathways, GLP-1RA may offer dual cardiometabolic and immunomodulatory protection, positioning these agents as promising candidates for broader therapeutic applications. However, several key questions remain regarding causality, the precise molecular mechanisms involved, and the extent to which these anti-inflammatory effects can be translated into effective therapies for nonmetabolic inflammatory diseases. **Keywords:** GLP-1 receptor agonists; autoimmune diseases; cardiometabolic disease; cardiovascular disease; immunomodulation; infectious diseases; inflammation; inflammatory bowel disease; neurodegeneration; sepsis. © The Author(s) 2026. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. ](https://pubmed.ncbi.nlm.nih.gov/40196933/) Thomsen RW, Mailhac A, Løhde JB, Pottegård A.Thomsen RW, et al.Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.Diabetes Obes Metab. 2025.PMID: 40196933Free PMC article.Review. * [ Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study. ](https://pubmed.ncbi.nlm.nih.gov/40897378/) Olbrich H, Kridin K, Zirpel H, Hernandez G, Sadik CD, Gaffal E, Thaçi D, Ludwig RJ.Olbrich H, et al.Br J Dermatol. 2026 Jan 6;194(1):59-66. doi: 10.1093/bjd/ljaf346.Br J Dermatol. 2026.PMID: 40897378 * [ GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers. ](https://pubmed.ncbi.nlm.nih.gov/41999297/) Chikatimalla R, Shah A, Shah T, Perry G, Banker H, Aggarwal K, Jain R.Chikatimalla R, et al.Ann Med. 2026 Dec;58(1):2660386. doi: 10.1080/07853890.2026.2660386. Epub 2026 Apr 18.Ann Med. 2026.PMID: 41999297Free PMC article.Review. * [ Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. ](https://pubmed.ncbi.nlm.nih.gov/38288136/) Alharbi SH.Alharbi SH.Ther Adv Endocrinol Metab. 2024 Jan 27;15:20420188231222367. doi: 10.1177/20420188231222367. eCollection 2024.Ther Adv Endocrinol Metab. 2024.PMID: 38288136Free PMC article.Review. * [ GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence. ](https://pubmed.ncbi.nlm.nih.gov/41930781/) Frey C.Frey C.Future Oncol. 2026 Apr;22(10):1221-1231. doi: 10.1080/14796694.2026.2654735. Epub 2026 Apr 3.Future Oncol. 2026.PMID: 41930781Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42219869) ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Anti-Inflammatory Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Inflammatory+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Anti-Inflammatory+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Anti-Inflammatory Agents* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Inflammatory+Agents%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Anti-Inflammatory+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Cardiovascular Diseases / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cardiovascular+Diseases%2Fdrug+therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cardiovascular+Diseases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Diabetes Mellitus, Type 2* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Mellitus%2C+Type+2%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Diabetes+Mellitus%2C+Type+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Diabetes Mellitus, Type 2* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Mellitus%2C+Type+2%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Diabetes+Mellitus%2C+Type+2) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Glucagon-Like Peptide-1 Receptor / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptide-1+Receptor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Glucagon-Like Peptide-1 Receptor Agonists* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucagon-Like+Peptide-1+Receptor+Agonists) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Inflammation* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Inflammation%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Inflammation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Neurodegenerative Diseases / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neurodegenerative+Diseases%2Fdrug+therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neurodegenerative+Diseases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) ## Substances * Anti-Inflammatory Agents Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Inflammatory+Agents%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Anti-Inflammatory+Agents%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Glucagon-Like Peptide-1 Receptor Agonists Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Glucagon-Like+Peptide-1+Receptor+Agonists%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) * Glucagon-Like Peptide-1 Receptor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucagon-Like+Peptide-1+Receptor%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Glucagon-Like+Peptide-1+Receptor%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42219869/) ## Related information * [ MedGen ](https://www.ncbi.nlm.nih.gov/medgen?linkname=pubmed_medgen&from_uid=42219869 "Related information in MedGen") ## Grants and funding * [ Deutsche Forschungsgemeinschaft ](https://pubmed.ncbi.nlm.nih.gov/?term=Deutsche+Forschungsgemeinschaft%5BGrants+and+Funding%5D&sort=date&sort_order=desc "All articles for grant Deutsche Forschungsgemeinschaft") * [ 520275106/German Research Foundation ](https://pubmed.ncbi.nlm.nih.gov/?term=520275106%2FGerman+Research+Foundation%5BGran
## Related Clinical Research

- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Impact of a 4-Week Vegan Diet on Inflammation and Biological Aging](https://medichelpline.com/clinical-feed/medical-news-today-0-just-4-weeks-on-a-vegan-diet-linked-to-changes-in-inflammation-aging.md)
- [Cardiovascular Disease Surpasses Cancer as Top Cause of Death in Hispanic Adults](https://medichelpline.com/clinical-feed/aha-news-3-cardiovascular-disease-tops-cancer-as-leading-cause-of-death-among-hispanic.md)
- [GLP-1 Receptor Agonists in Rheumatic Disease: Mechanisms, Evidence, and Clinical Considerations](https://medichelpline.com/clinical-feed/pubmed-42706128.md) (DOI: 10.3760/cma.j.cn112137-20260312-00692)
- [Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.